The dominant driver paradigm of cardiometabolic care
Clinical targeting of dysglycemia, hypertension, and dyslipidemia would be drastically reduced with a dominant driver paradigm in which abnormal adiposity is the most frequent dominant driver. With the advent of novel and effective pharmacotherapies for the treatment of abnormal adiposity, simplification of cardiometabolic-based chronic disease treatment is possible.
Authors
- Borja Ibáñez (ORCID: https://orcid.org/0000-0002-5036-254X)
- Pranav Mellacheruvu
- Shelley H. Liu (ORCID: https://orcid.org/0000-0003-2171-059X)
- Janet Johnson (ORCID: https://orcid.org/0000-0002-0456-4028)
- Masih A. Babagoli (ORCID: https://orcid.org/0000-0002-3753-3818)
- Joel Hernandez Sevillano
- Oscar Lorenzo
- Jeffrey I. Mechanick
- Yitong Chen
Institutions
- Hospital of the University of Pennsylvania (US)
- Instituto de Salud Carlos III (ES)
- Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition (ES)
- Spanish National Centre for Cardiovascular Research (ES)
- Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (ES)
- Hospital La Luz (ES)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- Mount Sinai Hospital (US)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- American Journal of Preventive Cardiology
- Published
- 2025-12-24
- DOI
- https://doi.org/10.1016/j.ajpc.2025.101389
- Primary Topic
- Adipokines, Inflammation, and Metabolic Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00